Valued at $44.0M at its early-stage round, Jan 2021. Nothing has traded since.
- ·Watch Primmune Therapeutics: the Monday email on marks, rounds and moves
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Primmune Therapeutics funding history
5 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Oct 2020 | Early Stage VC | $13.0M | ▮ | ▮ |
| Feb 2020 | Seed Round | $2.5M | ▮ | ▮ |
| Feb 2019 | Seed Round | $2.0M | ▮ | ▮ |
| Jul 2018 | Seed Round | $1.1M | ▮ | ▮ |
| Oct 2017 | Seed Round | $1.5M | ▮ | ▮ |
Membership and data by Private Market View
Primmune Therapeutics valuation
Primmune Therapeutics was valued at $44 million at its early-stage round in Jan 2021. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Primmune Therapeutics raised?
Primmune Therapeutics has raised $63.2 million in total; 5 of its rounds are on record, from 2017 on. The largest on record was a $2.5 million seed round in Feb 2020; the most recent was a $13 million early-stage round in Oct 2020.
Primmune Therapeutics has filed 6 Form Ds with the SEC since 2017, most recently in Nov 2020 ($13 million sold to 12 investors).
How Primmune Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Primmune Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →
Frequently asked about Primmune Therapeutics
- What is Primmune Therapeutics worth?
- Primmune Therapeutics is valued at $44.0M as of Oct 2026. Valued at $44.0M at its early-stage round, Jan 2021. Nothing has traded since.
- How much has Primmune Therapeutics raised?
- Primmune Therapeutics has raised $63.2M in total funding across 5 recorded rounds.
- When did Primmune Therapeutics last raise?
- Primmune Therapeutics last raised in Oct 2020 (Early Stage VC), raising $13.0M.